Cambridge, UK - 9th August 2016
Nuformix has received official notification from the Japanese PO of their decision to grant Nuformix’s patent for NXP001. Nuformix is pursuing global patent coverage for NXP001 asset, which offers multiple options for future development.
Nuformix Chief Executive Officer Dr Dan Gooding said: “The decision from the Japanese PO is excellent news for Nuformix. The Japanese application for NXP001 is our first in the region and represents another geography within which we have successfully navigated the patent approval process for a novel cocrystal drug form. This grant represents further validation of the broad patentability of pharmaceutical cocrystals, setting a precedent in Japan for future Nuformix patent filings. The Japanese market offers multiple product opportunities for this particular asset.”